Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Preparations	7.70B	-	6.45B	3.21B	2.64B
Preparations Growth	-	-	100.85%	21.69%	73.20%
Active Pharmaceutical Ingredient (API)	3.20B	-	3.44B	2.67B	2.72B
Active Pharmaceutical Ingredient (API) Growth	-	-	28.84%	-1.77%	0.77%
CDMO	1.03B	-	968.26M	1.08B	813.10M
CDMO Growth	-	-	-10.68%	33.32%	1.97%
Others	277.99M	-	448.25M	191.12M	191.89M
Others Growth	-	-	134.54%	-0.40%	-38.16%
Intersegment offset	-6.74B	-	-5.88B	-	-
Total	5.48B	-	5.43B	7.16B	6.37B
Total Growth	-	-	-24.14%	12.48%	19.38%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Mainland China	393.95M	342.51M	397.84M	-	-
Mainland China Growth	15.02%	-13.91%	-	-	-
United States of America	1.34B	1.43B	1.28B	-	-
United States of America Growth	-6.60%	11.99%	-	-	-
Europe	2.73B	2.37B	2.62B	-	-
Europe Growth	14.97%	-9.28%	-	-	-
Hong Kong	7.91M	7.20M	18.10M	-	-
Hong Kong Growth	9.83%	-60.19%	-	-	-
Other Countries/Regions	995.55M	1.11B	1.12B	-	-
Other Countries/Regions Growth	-10.25%	-1.11%	-	-	-
Foreign	-	-	-	6.51B	5.81B
Foreign Growth	-	-	-	12.09%	20.96%
China	-	-	-	649.85M	557.63M
China Growth	-	-	-	16.54%	5.04%
Total	5.46B	5.26B	5.43B	7.16B	6.37B
Total Growth	3.78%	-3.10%	-24.14%	12.48%	19.38%

Source: S&P Global Market Intelligence.